PetVivo Holdings, Inc. (PETV)
PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. Its flagship product is Spryng, an intra-articular injection administered by veterinarians to effectively alleviate lameness and joint conditions, such as osteoarthritis, in canines and equines. The company's development pipeline further includes seventeen therapeutic devices poised for both veterinary and human clinical applications. Founded in 2009, PetVivo Holdings, Inc. maintains its corporate headquarters in Minneapolis, Minnesota.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
PetVivo Holdings, Inc.
Recent SEC filings with analysis
- 8-KPetVivo Holdings (OTCQX: PETV) announced on September 22, 2026 that Diane Levitan resigned from its Board of Directors, with the company stating her departure…
- 8-KPetVivo Holdings (OTCQX: PETV) announced on September 22, 2026 that director Joseph Jasper resigned from the Board, with the company stating the resignation…